Selling to a Corporate Vet Group
Corporate consolidators pay what look like premium multiples. The arithmetic is more complicated than the headline number suggests.
Typical deal structure
A practice generating $1.5M collections at 25% EBITDA ($375K) gets a 10× EBITDA offer ($3.75M). Structure typically breaks down:
- Cash at close: $2.5-3M (65-80% of total consideration)
- Equity rollover: $400-800K in parent company units, 5+ year lockup, liquidity on recap or IPO
- Earnout: $300-500K tied to year 2-3 EBITDA targets
- Continued employment: 3-5 years at 27-33% of collections (vs. 40%+ as owner)
What you actually give up
- Income reduction post-sale. Your owner-equivalent income at $180K drops to associate-equivalent at $150K. Difference: $30K/yr × 3 years = $90K of lost income.
- Autonomy. Corporate-mandated lab partners, formularies, EMR systems. Many vets who sold report this as the biggest regret.
- Equity risk. If the parent company fails to exit at expected multiple, your rolled equity is worth less than face value. In recent years, several PE-backed consolidators have had bumpy exits.
Major corporate buyers and their reputations
| Group | Typical multiple | Equity rollover | Known for |
|---|---|---|---|
| Mars (Banfield, BluePearl, VCA) | 10-14× | Usually optional | Largest, most stable; standardized processes |
| NVA | 8-12× | Often significant | Preserves practice brand more; PE-backed (JAB Holdings) |
| MVP (Mission Veterinary Partners) | 9-12× | Often significant | Mid-size, more partnership-feel |
| Southern Veterinary Partners | 9-12× | Often significant | Regional focus in Southeast |
| Community Vet Partners (CVP) | 8-11× | Moderate | Newer entrant, smaller scale |
Private SBA-financed buyer alternative
A young associate or established vet in the area may buy at a 7-9× multiple via SBA financing. Lower headline number, but:
- All cash at close (bank funds it)
- No equity rollover, no earnout
- Faster close (3-5 months)
- No post-sale employment obligation
If the absolute dollar matters less than simplicity and certainty, a private sale often wins on risk-adjusted basis.
When corporate sale wins: You're within 3-5 years of retirement, want a clean exit, value the cash at close over maximum long-term upside, and are OK with 3 years of reduced autonomy.
When private sale wins: You want full exit with no obligations, no post-sale compensation strings, and the private-buyer price is within 25% of the corporate offer after risk-adjusting the equity rollover.
When private sale wins: You want full exit with no obligations, no post-sale compensation strings, and the private-buyer price is within 25% of the corporate offer after risk-adjusting the equity rollover.
Due diligence on the corporate buyer
- What's the parent's capital structure? PE-backed? Public?
- What's their track record on equity rollovers — have prior sellers actually gotten liquidity?
- Recent changes to compensation structure at existing practices under their umbrella?
- What do current owner-vets at their practices say (2-3 years post-sale)?
Related reading
Have a corporate offer on the table?
Fee-only advisor has reviewed offers across most major buyers. Free match.